MXPA05009193A - Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados. - Google Patents

Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados.

Info

Publication number
MXPA05009193A
MXPA05009193A MXPA05009193A MXPA05009193A MXPA05009193A MX PA05009193 A MXPA05009193 A MX PA05009193A MX PA05009193 A MXPA05009193 A MX PA05009193A MX PA05009193 A MXPA05009193 A MX PA05009193A MX PA05009193 A MXPA05009193 A MX PA05009193A
Authority
MX
Mexico
Prior art keywords
obesity
biaryltetrahydroisoquinoline
piperidines
treatment
receptor antagonists
Prior art date
Application number
MXPA05009193A
Other languages
English (en)
Spanish (es)
Inventor
Li Qiang
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MXPA05009193A publication Critical patent/MXPA05009193A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA05009193A 2003-02-28 2004-02-26 Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados. MXPA05009193A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45079903P 2003-02-28 2003-02-28
PCT/US2004/005780 WO2004078745A1 (en) 2003-02-28 2004-02-26 Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders

Publications (1)

Publication Number Publication Date
MXPA05009193A true MXPA05009193A (es) 2005-10-18

Family

ID=32962533

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009193A MXPA05009193A (es) 2003-02-28 2004-02-26 Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados.

Country Status (12)

Country Link
US (1) US7498441B2 (https=)
EP (1) EP1601664B1 (https=)
JP (1) JP4570165B2 (https=)
CN (1) CN1777596A (https=)
AR (1) AR043420A1 (https=)
AT (1) ATE393766T1 (https=)
CA (1) CA2517088A1 (https=)
DE (1) DE602004013427T2 (https=)
ES (1) ES2305735T3 (https=)
MX (1) MXPA05009193A (https=)
TW (1) TW200427679A (https=)
WO (1) WO2004078745A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008210455A1 (en) * 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as kinase inhibitors
AU2009274023A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
ES2402087T3 (es) 2008-07-23 2013-04-26 Vertex Pharmaceuticals Incorporated Inhibidores de la pirazolopiridina quinasa
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011001319A (es) * 2008-08-06 2011-04-05 Vertex Pharma Inhibidores de aminopiridina cinasa.
CA2760705A1 (en) 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
MX2012008643A (es) 2010-01-27 2013-02-26 Vertex Pharma Inhibidores de cinasas de pirazolopiridinas.
EP2528917B1 (en) 2010-01-27 2016-10-19 Vertex Pharmaceuticals Incorporated Pyrazolopyridines useful for the treatment of autoimmune, inflammatory or (hyper)proliferative diseases
WO2011094288A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
MX2018007844A (es) * 2015-12-22 2019-01-21 Jiangsu Hengrui Medicine Co Derivado de benzopiperidina, metodo de preparacion del mismo y su uso medico del mismo.
CN117343011A (zh) * 2023-09-28 2024-01-05 晨伫(杭州)生物科技有限责任公司 基于吡唑基-磺酰基-苯基骨架结构的化合物及其制备方法和应用、药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
CA2289574C (en) * 1997-05-30 2007-04-24 Neurosearch A/S 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
EP1299362A4 (en) * 2000-07-05 2004-11-03 Synaptic Pharma Corp SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE
PE20021081A1 (es) 2001-04-12 2002-12-18 Pharmacopeia Drug Discovery Aril y biaril piperidinas con actividad moduladora mch
CA2490531C (en) * 2002-06-27 2011-03-22 Schering Corporation Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity

Also Published As

Publication number Publication date
DE602004013427D1 (de) 2008-06-12
TW200427679A (en) 2004-12-16
DE602004013427T2 (de) 2009-06-04
ATE393766T1 (de) 2008-05-15
CN1777596A (zh) 2006-05-24
JP2006520399A (ja) 2006-09-07
EP1601664A1 (en) 2005-12-07
US20040176355A1 (en) 2004-09-09
US7498441B2 (en) 2009-03-03
WO2004078745A1 (en) 2004-09-16
CA2517088A1 (en) 2004-09-16
AR043420A1 (es) 2005-07-27
JP4570165B2 (ja) 2010-10-27
ES2305735T3 (es) 2008-11-01
EP1601664B1 (en) 2008-04-30

Similar Documents

Publication Publication Date Title
MXPA04003858A (es) Antagonistas de mch para el tratamiento de obesidad.
MXPA04004956A (es) Antagonistas de la hormona concentradora de melanina basados en la piperidina para tratamiento de la obesidad y de trastornos del sistema nervioso central.
MXPA04000707A (es) Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.
EE200300415A (et) Atsüülitud piperidiini derivaadid kui melanokortiin-4 retseptori agonistid ja farmatseutiline kompositsioon
NO20050749L (no) Nye alkyn-forbindelser med MCH-antagonistisk effekt og medikamenter inneholdende disse forbindelsene
MY146972A (en) Novel compounds as opioid receptor modulators.
TW200531689A (en) Therapeutic agents
DE60224404D1 (de) Substiuierte piperidine als melanocortinrezeptor-modulatoren
SI1735278T1 (sl) Agenti histamin h receptorja priprava in terapevtska uporaba
NO20070213L (no) Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser
TW200504034A (en) Therapeutic agents
WO2004005262A3 (en) New neuropeptide y y5 receptor antagonists
MXPA06003363A (es) Derivados de fenil-piperazina como moduladores de receptores muscarinicos.
MXPA05009193A (es) Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados.
WO2006044293A3 (en) Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
DK1957484T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
WO2005082893A3 (en) Histamine h3 receptor antagonists, preparation and therapeutic uses
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
MXPA05013596A (es) Antagonistas de hormona concentradora de melanina para el tratamiento de obesidad.
ATE432702T1 (de) Aminobenzimidazole als selektive melanin- konzentrierende hormon-rezeptorantagonisten zur behandlung von fettsucht und verwandten erkrankungen
MXPA05012572A (es) Derivado de 5-h-benzo[d]naft[2,1-b]azepina como antagonistas selectivos del receptor d1/d5 para el tratamiento de la obesidad y trastornos del sistema nervioso central.
MY143477A (en) Il-8 receptor antagonists
AU2003262926A1 (en) Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders
WO2005063697A3 (en) Substituted n-aryl amidines as selective d1 dopamine receptor antagonists for the treatment of obesity and cns disorders
WO2006019957A3 (en) Heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

Legal Events

Date Code Title Description
FG Grant or registration